May 1, 2019 - Denosumab appears to be effective in reducing the risk of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis. Treatment with denosumab does not increase the risk of cancer or death but might increase the risk of infection. However, more studies are required.
American Family Physician : Medicine by the Numbers
Jul 1, 1999 - Osteoporosis and low bone density are associated with a risk of fracture as a result of even minimally traumatic events. The estimated lifetime risk of osteoporotic fracture is as high as 50 percent, especially in white and Asian women. The use of caffeine, tobacco and steroids is ...
American Family Physician : Article
Jul 15, 2007 - Approximately one in six women will have a hip fracture during her lifetime, and approximately one in 35 of all women will die of complications from hip fracture.
American Family Physician : Point-of-Care Guides
Jul 1, 2005 - Raloxifene (60 mg daily for three years) will prevent one vertebral fracture, including asymptomatic fractures, for every 46 postmenopausal women with osteoporosis or presence of previous vertebral fractures. Raloxifene has not been shown to prevent nonvertebral fractures. It is unclear...
American Family Physician : FPIN's Clinical Inquiries
Jun 1, 2005 - What are the effects of treatments to prevent fractures in postmenopausal women?
American Family Physician : Clinical Evidence Handbook
navigate_before 1 navigate_next